Namenda

Treatment of Alzheimer's Disease

Namenda is specifically approved for the treatment of moderate to severe dementia of the Alzheimer's type. It is not typically used for mild symptoms of the disease.

How It Helps

This medication is intended to help manage the symptoms of Alzheimer's disease by potentially improving:

• Memory and thinking skills
• Awareness and focus
• The ability to perform daily activities and functions

Important Considerations

It is important to understand that Namenda is not a cure for Alzheimer's disease. It does not stop the underlying neurodegenerative process or prevent the disease from eventually getting worse. In some cases, healthcare providers may prescribe Namenda alongside other types of dementia medications, such as cholinesterase inhibitors, to help manage symptoms more effectively.

Glutamate Regulation

Namenda belongs to a class of medications known as NMDA receptor antagonists. It works by regulating the activity of glutamate, a chemical messenger in the brain that is essential for processing, storing, and retrieving information.

Protecting Brain Cells

In people with Alzheimer's disease, damaged brain cells may release too much glutamate. When glutamate levels are chronically high, it can overstimulate the brain's nerve cells, leading to further cell damage or death. Namenda helps by:

• Blocking certain receptors in the brain to prevent them from being overstimulated by excess glutamate.
• Allowing the normal signaling required for learning and memory to continue while protecting cells from toxic levels of the chemical.

Managing Symptoms

While Namenda does not cure Alzheimer's disease or stop the underlying disease process, it can help manage symptoms. By improving the communication between nerve cells, it may help maintain cognitive function and the ability to perform daily activities for a longer period.

Common Side Effects

The most frequently reported side effects of Namenda are typically mild and may include:

• Dizziness
• Headache
• Confusion
• Constipation
• Sleepiness or fatigue
• High blood pressure
• Back pain
• Cough
• Vomiting

Serious Side Effects

While rare, some side effects require immediate medical attention. Contact a doctor right away if you experience:

• Signs of a severe allergic reaction, such as hives, skin rash, or swelling of the face, tongue, or throat
• Difficulty breathing or swallowing
• Seizures
• Chest pain
• Fainting
• Sudden changes in vision
• Hallucinations or unusual changes in behavior
• Unusual weakness

Hypersensitivity

Namenda is contraindicated in individuals with a known hypersensitivity to memantine hydrochloride or any components of the medication.

Urinary Alkalization

Factors that increase the pH of urine can reduce the body's ability to clear memantine, potentially leading to increased drug levels and side effects. Conditions or changes that may raise urine pH include:

• Significant dietary changes, such as moving from a high-protein diet to a vegetarian diet.
• The use of certain medications, including sodium bicarbonate and carbonic anhydrase inhibitors.
• Severe urinary tract infections caused by certain bacteria.

Kidney and Liver Impairment

Dosage adjustments are typically necessary for patients with severe renal (kidney) impairment. The use of Namenda in patients with severe hepatic (liver) impairment should be approached with caution, as there is limited data regarding its safety in this group.

Seizure Risk

Caution is advised when prescribing Namenda to patients with a history of seizures. Although clinical trials did not demonstrate a significant increase in seizure frequency compared to a placebo, the potential risk remains a consideration for those with underlying seizure disorders.

Drug Interactions

The use of Namenda with other NMDA antagonists, such as amantadine, ketamine, or dextromethorphan, has not been systematically evaluated and should be approached with caution due to the potential for additive effects. Healthcare providers should be informed of all current medications before starting treatment.

Pregnancy

It is not known whether Namenda will harm an unborn baby. There are no adequate and well-controlled studies of memantine use in pregnant women. In animal studies, some developmental issues were observed, but only at doses that were also toxic to the mother. Because human data is lacking, healthcare providers typically recommend using this medication during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Breastfeeding

It is unknown if memantine passes into human breast milk or how it might affect a nursing infant. Because many medications are excreted in breast milk, caution is recommended for individuals who are breastfeeding. If you are nursing or planning to nurse, discuss the potential risks and benefits with your healthcare provider to determine the best course of action.

Oral Formulations

Namenda is available in two primary oral forms:

• Tablets: These are film-coated, immediate-release tablets designed for oral administration.
• Oral Solution: This is a liquid formulation of the medication, which may be used for patients who prefer a liquid or have difficulty swallowing tablets.

FDA Approval and Indications

Namenda (memantine) is approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe dementia associated with Alzheimer's disease. It belongs to a class of drugs known as NMDA receptor antagonists. Clinical evidence supports its use in managing symptoms of cognitive decline in advanced stages of the disease, though it is not FDA-approved for the treatment of mild Alzheimer's dementia.

Regulatory Oversight

• Prescription Status: Namenda is available only by prescription. It is not an over-the-counter medication.
• Boxed Warnings: There are no FDA boxed warnings (the agency's most serious safety warning) associated with Namenda.
• REMS: The FDA does not require a Risk Evaluation and Mitigation Strategy (REMS) for this medication.
• Controlled Substance: Memantine is not classified as a controlled substance.

Regulatory labeling for Namenda specifies that while the medication may help manage symptoms, it is not a cure for Alzheimer's disease and has not been shown to alter the underlying course of the disease. The FDA continues to monitor the safety of the drug through post-marketing surveillance and adverse event reporting.

Manufacturer Savings Programs

The manufacturer of Namenda often provides savings cards for eligible patients with commercial insurance to help reduce co-pay costs. These programs are generally not available to individuals covered by government insurance programs such as Medicare, Medicaid, or TRICARE.

Generic Availability

Memantine is the generic version of Namenda and is widely available. Choosing the generic form is often the most effective way to reduce the cost of the medication, as generics are typically priced significantly lower than brand-name drugs and are preferred by most insurance formularies.

Patient Assistance

Individuals who lack insurance coverage or meet certain income requirements may be eligible for patient assistance programs. These programs are designed to provide medications at a reduced cost or for free to those in financial need. Patients can check with the manufacturer or non-profit organizations to see if they qualify for such support.

Pharmacy Discounts

Various pharmacies and third-party services offer prescription discount cards that can be used to obtain a lower price on Namenda or its generic equivalent. These discounts are usually applied at the point of sale and cannot be used in conjunction with health insurance.